Plain-English translation of NCT07481526 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a large observational study following 3,000 adults with chronic kidney disease across 80 hospitals in China over nearly two years. Researchers will collect information from your medical records to understand how kidney disease is being treated in real-world settings and how patients fare over time. The study is not testing a new medication or procedure — instead, it's documenting current treatment practices and outcomes.
Chronic kidney disease affects millions of people, but doctors don't have enough real-world information about how different patients are managed across different hospitals and regions. This study aims to fill that gap by creating a comprehensive picture of kidney disease treatment in China, which can help improve care for future patients.
You likely qualify if…
You likely don't qualify if…
You would provide your written consent and then allow researchers to access and review your existing medical records from the hospital where you receive care. No additional visits, medications, or procedures are required beyond your normal kidney disease care. Researchers will track your health information for about 96 weeks (nearly 2 years) as part of a registry, using a secure electronic system to record data from your medical records.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Sponsor
AstraZeneca
Enrollment target
~3,000 participants
Started
February 2026
Primary completion
December 2028
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
AstraZeneca Clinical Study Information Center
Zhongshan Hospital Affiliated with Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.